Welcome to the e-CCO Library!

P098: Mucosal Microbiota Composition Predicts Infliximab Response in Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Gazouli, M.(1);Dovrolis , N.(2); Kolios, G.(2);
Created: Friday, 11 February 2022, 3:52 PM
P098: Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lee, J.(1)*;Kim, G.(1);Kim, J.C.(1);Park, J.H.(1);Han, C.(1);Kim, M.(1);
Created: Friday, 14 July 2023, 10:48 AM
P098: Oregonin inhibits intestinal epithelial injury by modulating heme oxygenase-1
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Seo G.S.*1, Chi J.-H.2, Jin H.3, Lee S.H.2

Created: Wednesday, 20 February 2019, 10:36 AM
P098: Role of serum lysol oxidase like 2 in Crohn's disease and modulation to biological treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. J. Garcia Garcia*1, A. Garcia Blanco2, B. Castro Senosiain1, M. Pascual Mato1, C. Del Pozo Calzada1, J. Crespo Garcia1, M. Rivero Tirado1

Created: Friday, 22 February 2019, 9:41 AM
P099 Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker in collagenous colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.A. Walaas1, I. Bakke1,2, A.V. Granlund1,3, C. Escuderos-Hernândez4, T. Bruland1,2, E.S. Røyset1,5, S. Thorsvik2,6, A. Münch4,7, A.E. Østvik1,2,6, A.K. Sandvik1,2,3,6

Created: Thursday, 30 January 2020, 10:12 AM
P099: Altered intrinsic brain function in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Thomann A.*1, Griebe M.2, Thomann P.3, Reindl W.4, Wolf C.3

Created: Wednesday, 20 February 2019, 10:36 AM
P099: Evaluation of endoscopic mayo score with an artificial intelligence algorithm
Year: 2021
Source: ECCO'21 Virtual
Authors: Kani, H.T.(1);Ergenc, I.(1);Polat, G.(2);Ozen Alahdab, Y.(1);Temizel, A.(2);Atug, O.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P099: IL-33 activates CD73-expressing cells promoting tumorigenesis during colitis-associated colorectal cancer
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lopetuso, L.R.(1)*;Privitera, G.(2);Di Martino, L.(3);Scaldaferri, F.(1);Gasbarrini, A.(1);Cominelli, F.(3);De Salvo, C.(2);Pizarro, T.(2);
Created: Friday, 14 July 2023, 10:48 AM
P099: Inhibitory effect of 6-aminopyridin-3-ol analogues on TNF-α-induced monocyte-colon epithelial cell adhesion and TNBS-induced rat colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B.-S. Jeong*1, S. Banskota1, P. Grung1, T.-g. Nam2, J.-A. Kim1

Created: Friday, 22 February 2019, 9:49 AM
P099: Patients with ulcerative colitis show increased Treg number in peripheral blood after 1 year of anti-TNF therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Kyurkchiev*1, E. Ivanova-Todorova1, Z. Spasova2, T. Velikova1, M. Petkova2, E. Krasimirova1, K. Tumangelova - Yuzeir1, L. Mateva - Vladimirova2

Created: Friday, 22 February 2019, 9:41 AM
P099: Postprandial intestinal motility and related physiology in active small-bowel Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Khalaf1,2, C.L. Hoad2,3, A. Menys4, S. Radford2, A. Nowak2, S. Paparo1,2, M. Lingaya2, Y. Falcone2, G. Singh2, S.A. Taylor4, R.C. Spiller1,2, P.A. Gowland3, L. Marciani1,2, G.W. Moran1,2*

Created: Thursday, 21 February 2019, 9:14 AM
P099: Serum proteomic analysis reveals novel biomarkers associated with disease activity in pediatric patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Werner, L.(1);Weiss, B.(2);Matar, M.(1);Shamir, R.(1);Shouval, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P100 CD161 levels are reduced in all subpopulations of T-cell colonic mucosal lymphocytes in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Tristan, A. Carrasco, A. Martín-Cardona, Y. Zabana, M. Aceituno, A. Raga, X. Andújar, B. Arau, P. Ruiz-Ramírez, L. Ruiz-Campos, F. Fernández-Bañares, M. Esteve

Created: Thursday, 30 January 2020, 10:12 AM
P100: Atypical Anti-Neutrophil Cytoplasmatic Antibodies Are Antibodies Against Neutrophil Extracellular Traps: A Novel Pathophysiological Mechanism In Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mendieta Escalante, E.A.(1)*;Faber, K.N.(1);Hermoso Ramello, M.(1);Parada-Venegas, D.(1);Bourgonje, A.(2);Roozendaal, C.(3);Dijkstra, G.(1);
Created: Friday, 14 July 2023, 10:48 AM
P100: Effects of a narrow spectrum kinase inhibitor and selective kinase inhibitors on the intestinal pro-inflammatory immune response in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. R. Foster*1, P. Biancheri2, Y. Solanke1, S. Sirohi1, M. C. Fyfe1, A. Rowley1, T. T. MacDonald2, E. Wood3, S. Webber1, C. A. Walshe1

Created: Friday, 22 February 2019, 9:49 AM
P100: Guanosine prevents nuclear factor-κB nuclear translocation ameliorating experimental colitis in rats
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.G. Zizzo1,2*, G. Caldara3, A. Bellanca2, D. Nuzzo4, M. Di Carlo4, R. Serio1

Created: Thursday, 21 February 2019, 9:14 AM
P100: Higher yield of serrated and adenomatous dysplasia detected with chromoendoscopy when compared with high-definition in patients with Primary Sclerosing Cholangitis and Inflammatory colitis.
Year: 2021
Source: ECCO'21 Virtual
Authors: Gupta, V.(1);Hartery, K.(2);Oxford IBD Cohort Investigators, I.(2);Bassett, P.(2);Culver, E.(2);East, J.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P100: Intestinal epithelial cells under endoplasmic reticulum stress boosts serine proteolytic activity and modulates barrier function
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Solà Tapias N., Denadai-Souza A., Rolland-Fourcade C., Blanpied C., Dietrich G., Bonnart C., Edir A., Rolland C., Deraison C., Vergnolle N., Barreau F.

Created: Wednesday, 20 February 2019, 10:36 AM
P100: Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Cheung*1, T. Gupta1, A. Olsson-Brown2, S. Subramanian3, M. Payne4, M. Middleton4, O. Brain1

Created: Friday, 22 February 2019, 9:41 AM
P100: Serum inflammatory protein profiling to corroborate selection of therapy naïve moderate-to-severe pediatric Crohn’s disease patients eligible for first-line infliximab treatment
Year: 2022
Source: ECCO'22
Authors: Jongsma , M.M.E.(1);Costes , L.M.M.(2);Tindemans , I.(2);Cozijnsen , M.A.(1);Raatgreep , R.H.C.(2);van Pieterson , M.(1);Li , Y.(3);Escher , J.C.(1);de Ridder , L.(1);Samsom , J.N.(2);
Created: Friday, 11 February 2022, 3:52 PM